Head-to-Head Studies Between DOACs
Current Evidence Landscape
- The American Society of Hematology 2020 guidelines explicitly state that no systematic reviews or randomized trials comparing different DOACs head to head were found, with the certainty in comparative evidence between DOACs judged "very low" for all relevant outcomes 1
- Subgroup analyses found no interaction between specific DOAC agents and risk of mortality, PE, symptomatic DVT, or major bleeding when compared indirectly against vitamin K antagonists 1
Ongoing Research Status
- The CARAVAGGIO trial (NCT03045406) comparing apixaban versus dalteparin in cancer patients was recruiting as of 2019, but this compares a DOAC to LMWH, not DOAC-to-DOAC 2
Current Clinical Decision-Making
- Important selection factors for DOACs include renal function, with dabigatran having ~80% renal clearance versus apixaban 25% renal clearance 1
- Hepatic function is also a consideration, with dabigatran being the least reliant on hepatic clearance 1
- Dosing frequency, need for food intake with medication, and requirement for initial parenteral anticoagulation are also factors, with dabigatran and edoxaban requiring LMWH lead-in, while rivaroxaban and apixaban do not 1, 4, 5
Clinical Implications
- All DOACs are considered equivalent in the absence of head-to-head data, with selection based on patient-specific factors rather than superior efficacy of one agent 1
- Prospective research studies comparing different DOACs would be particularly valuable in selected populations such as individuals with renal insufficiency, liver disease, or morbid obesity 1